PUBLISHER: TechNavio | PRODUCT CODE: 1626453
PUBLISHER: TechNavio | PRODUCT CODE: 1626453
Gastroparesis Drugs Market 2025-2029
The gastroparesis drugs market is forecasted to grow by USD 1338.7 mn during 2024-2029, accelerating at a CAGR of 3.5% during the forecast period. The report on the gastroparesis drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising global burden of diabetes, increasing prevalence of gastroparesis, and increasing awareness about gastroparesis.
Market Scope | |
---|---|
Base Year | 2025 |
End Year | 2029 |
Series Year | 2025-2029 |
Growth Momentum | Accelerate |
YOY 2025 | 3.4% |
CAGR | 3.5% |
Incremental Value | $1338.7 mn |
Technavio's gastroparesis drugs market is segmented as below:
By Drug Class
By Disease Type
By Geographical Landscape
This study identifies the increasing growth opportunities in emerging markets as one of the prime reasons driving the gastroparesis drugs market growth during the next few years. Also, increasing number of clinical research and rising funding in healthcare industry will lead to sizable demand in the market.
The report on the gastroparesis drugs market covers the following areas:
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading gastroparesis drugs market vendors that include Abbott Laboratories, AbbVie Inc., Aclipse Therapeutics, ANI Pharmaceuticals Inc., Bausch Health Companies Inc., Cadila Pharmaceuticals Ltd., Eisai Co. Ltd., Evoke Pharma Inc., GlaxoSmithKline Plc, Ipca Laboratories, Johnson and Johnson Inc., Medtronic Plc, Neurogastrx Inc., Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., Processa Pharmaceuticals Inc., Rhythm Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., Theravance Biopharma Inc., and Vanda Pharmaceuticals Inc.. Also, the gastroparesis drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Exhibits: